Quick answer: A landmark 2017 randomized controlled trial published in BMC Medicine (the SMILES trial) found that a 12-week dietary intervention reduced depression scores more than supportive psychotherapy, with 32% of participants in the dietary intervention group achieving remission versus 8% in the control group — an effect size larger than most antidepressant trials. This study crystallized a paradigm shift: depression, anxiety, and other psychiatric conditions are not primarily neurotransmitter deficiencies correctable by SSRI prescriptions, but complex inflammatory, metabolic, and gut-brain axis disorders requiring root-cause investigation. Functional psychiatry integrates neuroscience, nutritional biochemistry, immunology, and emerging psychopharmacology to address the biological underpinnings of mental illness.
The Neuroinflammation Model of Depression
The serotonin deficiency hypothesis of depression — the foundational justification for SSRI prescriptions — has been substantially challenged by the scientific evidence. A comprehensive 2022 umbrella review by Moncrieff and colleagues (Molecular Psychiatry), synthesizing meta-analyses across six research domains, found no consistent evidence that depression is associated with lower serotonin activity or concentration. Serotonin transporter (5-HTT) gene variants showed no association with depression vulnerability. Tryptophan depletion studies that lower serotonin synthesis did not consistently produce depression in healthy volunteers.
The emerging replacement framework — the neuroinflammation model — has substantially stronger evidentiary support. Multiple meta-analyses, including Dowlati 2010 (Biological Psychiatry, n=1,200) and Haapakoski 2015 (Brain, Behavior, and Immunity), demonstrate that depressed patients show significantly elevated inflammatory cytokines: IL-6 (by approximately 62%), TNF-α (by 34%), and CRP. Critically, this is not simply comorbid inflammation — longitudinal studies demonstrate that elevated inflammatory markers predict subsequent depression onset in initially healthy individuals, establishing a causal direction.
The mechanism linking neuroinflammation to depressive symptoms is mediated primarily by the kynurenine pathway. Inflammatory cytokines, particularly IL-6 and IFN-γ, activate indoleamine 2,3-dioxygenase (IDO) — an enzyme that shunts tryptophan metabolism away from serotonin synthesis and toward the kynurenine pathway. Kynurenine is further metabolized to quinolinic acid, an NMDA receptor agonist that generates reactive oxygen species and induces glutamate excitotoxicity in the hippocampus and prefrontal cortex. This explains the spatial pattern of brain volume loss in depression: hippocampal volume reduction correlates with depression duration and severity, and is mediated by quinolinic acid-induced neuronal death and suppressed BDNF signaling.
Therapeutic implications of the neuroinflammation model are substantial. Anti-inflammatory interventions — omega-3 fatty acids, curcumin, dietary pattern modification, exercise, sleep restoration, gut barrier repair — are predicted to have antidepressant effects in patients with elevated inflammatory markers. Indeed, subgroup analyses of clinical trials consistently find that omega-3 supplementation and anti-inflammatory interventions show the largest antidepressant effects in patients with elevated baseline CRP — and negligible effects in low-inflammation patients. This suggests a biologically informed patient stratification approach that is entirely absent from current psychiatric practice.
The Gut-Brain Axis in Mental Health
The gut microbiome influences brain function through multiple bidirectional pathways that collectively constitute the gut-brain axis: the vagus nerve (which carries 80% of its signals from gut to brain, not brain to gut), the enteric nervous system (containing more neurons than the spinal cord), short-chain fatty acid signaling, cytokine-mediated immune communication, enteroendocrine cell production of serotonin precursors, and direct neurotransmitter production by gut bacteria. The clinical significance of these pathways is increasingly established.
Valles-Colomer and colleagues (2019, Nature Microbiology) analyzed gut microbiome data from 1,054 individuals in the Flemish Gut Flora Project, correlating bacterial species with validated mental health questionnaires. Two genera — Coprococcus and Dialister — were consistently depleted in individuals with depression, and Coprococcus depletion was associated with reduced butyrate production and reduced DOPAC (a dopamine metabolite), suggesting a mechanistic link between gut bacteria, butyrate production, and dopamine signaling. These findings were replicated in an independent Dutch cohort.
Psychobiotics — probiotics with documented mental health benefits — have moved from speculative to evidence-based territory. A 2019 systematic review by Alli and colleagues in Nutrients found that probiotic supplementation significantly reduced depression scores in 7 of 10 RCTs reviewed, with the strongest effects seen in strains including Lactobacillus rhamnosus, L. helveticus, Bifidobacterium longum, and B. infantis. Pinto-Sanchez 2017 (Gastroenterology) found that B. longum NCC3001 reduced depression scores in IBS patients by 64% while simultaneously reducing amygdala reactivity on functional MRI — a direct demonstration of gut microbiome effects on limbic circuitry.
The short-chain fatty acid butyrate occupies a central position in gut-brain communication. Produced by bacterial fermentation of dietary fiber, butyrate is the primary energy substrate for colonocytes, maintains intestinal barrier integrity, and acts as an epigenetic modulator by inhibiting histone deacetylases (HDACs) — an action that upregulates BDNF expression and promotes neuroplasticity. Studies in germ-free mice show elevated stress responses, increased anxiety behavior, and reduced hippocampal BDNF — all normalized by colonization with specific bacteria or butyrate supplementation. Practical dietary implications: 30+ plant species per week consistently generates the microbial diversity and substrate availability for robust butyrate production.
Nutritional Psychiatry: The Evidence Base
The SMILES trial (Supporting the Modification of Lifestyle in Lowered Emotional States), published by Jacka and colleagues in BMC Medicine (2017), was the first RCT specifically designed to test whether dietary improvement could treat major depressive disorder. 67 participants with moderate-to-severe MDD were randomized to 12 weeks of dietary intervention (a Mediterranean-style “ModiMedDiet”) or social support control. The dietary intervention group showed mean reductions of 11 points on the MADRS depression scale versus 4 points in controls — a clinically meaningful difference with a large effect size (Cohen’s d = 1.16). 32% of dietary participants achieved remission versus 8% of controls. The dietary change was cost-effective: approximately $138 AUD per person over 3 months.
Omega-3 fatty acids have the strongest evidence base among individual nutritional interventions for mood disorders. A 2019 meta-analysis by Liao and colleagues (Translational Psychiatry), analyzing 26 RCTs with 2,160 participants, found significant antidepressant effects (SMD = -0.40), with the benefit concentrated in formulations with higher EPA:DHA ratios. EPA (eicosapentaenoic acid) is specifically anti-inflammatory — it competes with arachidonic acid as a substrate for cyclooxygenase and lipoxygenase, reducing pro-inflammatory prostaglandin and leukotriene production. DHA (docosahexaenoic acid) is critical for neuronal membrane fluidity and serotonin receptor function. The practical recommendation for depression: 2–4g/day of EPA+DHA with EPA comprising at least 60% of the formula (EPA:DHA ratio ≥ 2:1).
Magnesium deficiency — present in 45–60% of the US population — directly impairs NMDA receptor function, HPA axis regulation, and serotonin synthesis. Dietary magnesium intake has declined 50% over the last century due to soil depletion and food processing, and serum magnesium is an unreliable indicator of intracellular depletion (red blood cell magnesium provides better assessment). A 2017 RCT by Tarleton and colleagues (PLOS ONE) found that 248mg of elemental magnesium daily for 6 weeks significantly reduced PHQ-9 depression scores (from 10.3 to 6.7) and GAD-7 anxiety scores in patients with mild-to-moderate depression. Magnesium glycinate (providing highest bioavailability with minimal laxative effect) at 300–400mg elemental per day is a rational first-line nutritional intervention in depression.
Methylation biochemistry is directly involved in psychiatric disorders. S-adenosyl methionine (SAMe) donates methyl groups to over 100 biological reactions, including neurotransmitter synthesis (dopamine, serotonin, norepinephrine), myelin maintenance, phosphatidylcholine synthesis, and DNA/histone methylation. MTHFR polymorphisms (particularly C677T and A1298C) reduce 5,10-methylenetetrahydrofolate reductase activity, impairing conversion of folate to 5-methylTHF — the active form that regenerates methionine and ultimately SAMe. Papakostas and colleagues (2012, American Journal of Psychiatry) demonstrated that L-methylfolate (15mg/day) augmented antidepressant response in SSRI non-responders, with the largest benefit in patients with MTHFR variants and elevated inflammatory markers.
The HPA Axis, Cortisol, and Anxiety Disorders
Anxiety disorders — generalized anxiety disorder, panic disorder, social anxiety, PTSD — share a common neurobiological substrate: dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis and its interaction with limbic fear circuits (amygdala, hippocampus, prefrontal cortex). Cortisol, the HPA’s primary output hormone, has bidirectional effects on anxiety: acute cortisol mobilizes appropriate threat responses, but chronic hypercortisolemia promotes hippocampal atrophy (the hippocampus provides negative feedback on cortisol secretion, creating a vicious cycle), increases amygdala reactivity, and suppresses prefrontal executive function — exactly the neuroanatomical changes that produce generalized anxiety and emotional dysregulation.
DUTCH Complete testing (dried urine hormone testing) provides the most comprehensive assessment of cortisol biology available outside research settings. It measures free cortisol at four time points across the day (capturing the cortisol awakening response, which is disrupted in anxiety and depression), total cortisol metabolites (reflecting adrenal output volume), the cortisone/cortisol ratio (reflecting 11β-HSD1 activity — the enzyme that reactivates cortisol in peripheral tissues and the brain), and DHEA/DHEA-S levels (which counter-regulate cortisol’s catabolic and anxiety-promoting effects). This profile identifies whether anxiety symptoms arise from excessive cortisol production, impaired cortisol clearance, or low DHEA relative to cortisol — each requiring different interventions.
Ashwagandha (KSM-66 extract) has the most rigorous evidence among adaptogenic herbs for anxiety and HPA axis regulation. Chandrasekhar and colleagues (2012, Indian Journal of Psychological Medicine) conducted a double-blind RCT of 300mg KSM-66 twice daily in adults with chronic stress, finding significant reductions in serum cortisol (by 27.9%), PSS stress scores, and HAM-A anxiety scores compared to placebo. The proposed mechanisms include withanolide inhibition of NF-κB (reducing inflammatory cytokine production), modulation of GABAergic transmission, and direct cortisol-lowering effects. Phosphatidylserine (400–800mg/day) provides complementary HPA axis support through its role in cortisol receptor signaling and its documented ability to blunt post-exercise cortisol spikes in athletes.
ADHD: Beyond Dopamine — The Nutritional and Inflammatory Root Causes
Attention-deficit hyperactivity disorder (ADHD) is characterized by dysregulation of the dopamine and norepinephrine systems in prefrontal cortex circuits governing executive function. The dominant pharmacological approach targets dopamine reuptake transporters (stimulant medications). Functional medicine adds an upstream lens: what are the biological drivers of dopamine signaling deficiency, and can they be modified?
Iron deficiency specifically impairs dopamine synthesis and receptor function — dopamine is synthesized from tyrosine via tyrosine hydroxylase, which requires iron as a cofactor. Cortese and colleagues (2012) found that ferritin below 30 ng/mL was present in 84% of ADHD children versus 18% of controls, and that low ferritin correlated with ADHD severity (r = -0.35). A clinical trial by Konofal and colleagues (2008, Pediatric Neurology) found that 80mg/day of ferrous sulfate for 12 weeks produced significant improvements in ADHD symptoms (Cohen Rating Scale) comparable to stimulant medication effect sizes — in iron-deficient ADHD children specifically. Ferritin testing should be routine in all ADHD evaluations.
Omega-3 fatty acids — specifically the EPA:DHA balance — are relevant to ADHD pathophysiology through multiple mechanisms: DHA is a primary structural component of neuronal membranes and myelin, EPA reduces neuroinflammation (elevated in ADHD brains), and omega-3 deficiency reduces dopamine receptor density and synaptic vesicle release probability. A 2012 Cochrane review by Gillies and colleagues found modest but consistent improvements in ADHD symptoms from omega-3 supplementation across multiple trials. A 2011 RCT by Milte and colleagues found that high-EPA supplementation (558mg EPA + 174mg DHA) improved reading, spelling, and behavior scores in children with ADHD and learning difficulties. Omega-3 supplementation is a rational evidence-based adjunct, particularly in children with documented omega-3 deficiency (omega-3 index).
Zinc is a cofactor for dopamine synthesis (via DOPA decarboxylase) and modulates NMDA receptor function. Multiple studies document lower serum and hair zinc in ADHD versus controls. A 2004 RCT by Bilici and colleagues (Progress in Neuro-Psychopharmacology and Biological Psychiatry) found that 150mg/day of zinc sulfate for 12 weeks significantly reduced hyperactivity and impulsivity scores in ADHD children versus placebo. Food additives (particularly synthetic dyes Red 40, Yellow 5, Yellow 6, and sodium benzoate) have documented dose-dependent effects on ADHD symptoms — the 2007 McCann et al. Lancet study triggered the European Food Safety Authority warning and European Union labeling requirements. An elimination trial remains clinically justified.
Ketamine and Psychedelic-Assisted Therapy: The Evidence
Ketamine and Psychedelic-Assisted Therapy: The Evidence
The development of ketamine as a rapid-onset antidepressant represents the most significant advance in psychiatric pharmacology in 60 years. Zarate and colleagues (2006, Archives of General Psychiatry) demonstrated that a single subanesthetic intravenous infusion of ketamine (0.5 mg/kg over 40 minutes) produced rapid, robust antidepressant effects within 2 hours, peaking at 24 hours, in 71% of treatment-resistant MDD patients — compared to 0% of placebo patients. This effect is remarkable both for its speed (standard antidepressants require 4–6 weeks) and its activity in patients who had failed multiple previous treatments.
The mechanism of ketamine’s antidepressant action is NMDA receptor antagonism-triggered AMPA receptor upregulation, downstream BDNF release, and mTOR pathway activation in prefrontal neurons — producing rapid synaptogenesis and restoration of atrophied dendritic spines that characterize the depressed brain. The synaptogenesis occurs within hours of a single infusion and is visible on electron microscopy. Esketamine (Spravato), the S-enantiomer delivered intranasally, received FDA approval in 2019 for treatment-resistant depression. Multiple systematic reviews now confirm the acute antidepressant effect across IV ketamine protocols, though durability is limited (typically 2–3 weeks per infusion), necessitating maintenance protocols.
Psilocybin-assisted therapy has accumulated striking clinical evidence over the past decade, particularly from the Johns Hopkins group and Imperial College London. Davis and colleagues (2021, JAMA Psychiatry) conducted a double-blind RCT of psilocybin (25mg) versus placebo in 24 treatment-resistant MDD patients, finding that psilocybin produced rapid, significant reductions in depression scores that were maintained at 4-week follow-up, with 71% of participants classified as responders and 54% achieving remission. Carhart-Harris and colleagues (2021, NEJM) compared psilocybin-assisted therapy to escitalopram in MDD, finding comparable antidepressant effects but with psilocybin showing superior outcomes in secondary measures including emotional connectedness and quality of life.
MDMA-assisted psychotherapy for PTSD has the most mature trial evidence among psychedelic therapies. The MAPS Phase 3 trial (Mitchell 2021, Nature Medicine) randomized 90 PTSD patients to MDMA-assisted therapy versus therapy with placebo. 67% of MDMA patients no longer met PTSD diagnostic criteria at 18-week follow-up versus 32% of placebo patients — a remarkable response rate for what was entirely treatment-resistant PTSD. FDA advisory committee review in 2024 acknowledged the compelling evidence while raising concerns about blinding and trial design; regulatory status continues to evolve. The mechanisms involve MDMA-induced oxytocin release, reduced amygdala reactivity, and facilitated extinction of fear memories during the therapeutic window created by the pharmacological state.
Thyroid and Hormonal Contributions to Psychiatric Symptoms
Subclinical hypothyroidism — TSH above 2.5–3.0 mIU/L with normal T4 — is present in 4–10% of the general population and disproportionately in patients seeking care for depression and anxiety. Thyroid hormone directly regulates serotonin receptor expression, dopamine synthesis, BDNF production, and mitochondrial function in neurons. The psychiatric symptoms of thyroid deficiency — cognitive slowing, depressed mood, anxiety, fatigue, poor memory — are frequently misattributed to primary psychiatric conditions, particularly in patients with Hashimoto’s thyroiditis where the autoimmune process may produce TSH fluctuations that generate mood instability.
The DIO2 (type 2 deiodinase) enzyme converts T4 to the active T3 within neurons and pituitary cells. A common DIO2 polymorphism (Thr92Ala-DIO2, present in 12% of the population as homozygotes) impairs this conversion specifically in the brain, meaning patients with this variant may have normal serum T3 but impaired neuronal T3 — a state not detected by standard thyroid testing. Bunevicius and colleagues (2001, NEJM) demonstrated that T3 addition to standard T4 therapy improved cognitive function and mood in hypothyroid patients, with the greatest benefit in DIO2 polymorphism carriers. Functional psychiatry includes complete thyroid panel (TSH, free T4, free T3, reverse T3, anti-TPO, anti-thyroglobulin) and DIO2 pharmacogenomic testing in patients with treatment-resistant depression.
Testosterone deficiency in men is independently associated with depression, anhedonia, and cognitive decline — symptoms that closely mimic MDD and often do not respond to antidepressants alone. A meta-analysis by Zarrouf and colleagues (2009) found that testosterone therapy significantly improved mood in men with hypogonadism. Estrogen fluctuations drive perimenopausal and postpartum depression through direct effects on serotonin transporter expression, MAO-A activity, and amygdala reactivity. Allopregnanolone (a progesterone metabolite and GABA-A receptor positive allosteric modulator) has received FDA approval as brexanolone (Zulresso) for postpartum depression, demonstrating the direct biological link between progesterone metabolism and mood regulation.
Functional Psychiatry Testing Panel
Comprehensive functional psychiatric evaluation includes laboratory assessment targeting the modifiable biological drivers of mental illness. The core panel includes: complete blood count with differential (ruling out anemia, infection, autoimmune blood dyscrasias); comprehensive metabolic panel; thyroid panel (TSH, free T4, free T3, reverse T3, anti-TPO, anti-thyroglobulin); sex hormones (testosterone total and free, estradiol, progesterone, DHEA-S, SHBG); inflammatory markers (hs-CRP, IL-6 if available, ferritin); nutritional assessment (25-OH vitamin D, folate, B12/methylmalonic acid, magnesium RBC, zinc, omega-3 index); fasting glucose and insulin (insulin resistance is independently associated with depression); and DUTCH Complete hormonal testing for HPA axis characterization.
Genetic testing adds significant precision. MTHFR variants (C677T, A1298C) guide methylfolate supplementation. COMT Val158Met polymorphism affects dopamine catabolism rate in prefrontal cortex — Val/Val homozygotes catabolize dopamine rapidly and may respond better to dopaminergic strategies, while Met/Met individuals are more vulnerable to catechol excess from stimulants. CYP450 pharmacogenomic panel (CYP2D6, CYP2C19, CYP3A4) guides antidepressant selection — approximately 7% of the population are poor CYP2D6 metabolizers who accumulate toxic levels of multiple SSRIs and TCA antidepressants at standard doses. This testing explains a substantial fraction of antidepressant “non-response” that is actually toxicity at therapeutic doses.
Frequently Asked Questions
Can diet really treat depression? The evidence is increasingly clear that diet significantly modifies depression risk and treatment response. The 2017 SMILES RCT demonstrated a Mediterranean-style dietary intervention achieving 32% remission in MDD (versus 8% in controls) — an effect size comparable to antidepressants. Multiple cohort studies show that Mediterranean and whole-food dietary patterns are associated with 25–35% lower depression incidence. Diet does not replace established psychiatric treatment for severe depression, but it is a powerful adjunct that addresses biological root causes including neuroinflammation, gut dysbiosis, and nutrient deficiency.
What is the difference between regular psychiatry and functional psychiatry? Conventional psychiatry primarily focuses on symptom-based diagnosis and pharmacological treatment — assigning DSM diagnoses and prescribing medications that modulate neurotransmitter signaling. Functional psychiatry adds root-cause investigation: comprehensive lab testing to identify inflammatory, hormonal, nutritional, and genetic contributors; gut microbiome and gut-brain axis assessment; detailed lifestyle analysis (sleep, exercise, diet, stress, toxic exposures); and interventions targeting these upstream causes alongside or instead of symptomatic pharmacotherapy. The goal is restoration of biological function, not indefinite symptom suppression.
What nutrients are most important for anxiety and depression? Based on current evidence, the most clinically impactful nutritional interventions for mood disorders are: omega-3 fatty acids (2–4g/day with high EPA ratio) addressing neuroinflammation and membrane function; magnesium glycinate (300–400mg elemental/day) addressing HPA axis dysregulation and NMDA receptor function; methylated B vitamins (L-methylfolate 1–15mg/day, methylcobalamin) addressing methylation capacity for neurotransmitter synthesis; vitamin D3 (targeting 50–80 ng/mL) for serotonin synthesis and neuroprotection; and zinc (15–30mg/day) for dopamine synthesis and NMDA receptor modulation.
Is ketamine treatment safe for depression? Clinical ketamine infusion (0.5 mg/kg IV over 40 minutes in monitored settings) has a strong short-term safety record across thousands of documented administrations. Transient dissociation, elevated blood pressure, and nausea during infusion are common but manageable. Long-term concerns center on bladder toxicity (documented in high-frequency recreational users, not standard clinical protocols) and abuse potential in patients with active substance use disorders. Esketamine nasal spray (Spravato) carries FDA REMS requirements including in-office administration with monitoring. Ketamine is most appropriate for treatment-resistant depression, acute suicidality, and patients needing rapid symptom relief.
Can functional medicine help with PTSD? Functional medicine addresses several biological variables that maintain PTSD: HPA axis dysregulation (elevated or blunted cortisol rhythm), sleep architecture disruption, elevated inflammatory markers, and compromised hippocampal neurogenesis (BDNF-dependent). Nutritional interventions (omega-3, magnesium, BDNF-stimulating exercise) alongside HPA axis support represent meaningful adjuncts to evidence-based trauma therapies (EMDR, prolonged exposure, CPT). The MDMA-assisted psychotherapy trials represent the most dramatic example of a biological intervention transforming treatment-resistant PTSD — though access remains limited pending regulatory approval.
Functional psychiatry does not reject conventional psychiatric treatment — it enriches it with the biological depth that symptom-based diagnosis cannot provide. By identifying neuroinflammation, gut dysbiosis, HPA axis patterns, nutritional deficiencies, hormonal imbalances, and pharmacogenomic variables, functional psychiatry makes treatment precise and personalizes interventions to the individual’s actual biology. If you are experiencing depression, anxiety, or cognitive symptoms that have not responded to standard treatment, or if you want to understand the root causes of your mental health challenges, we invite you to schedule a comprehensive evaluation at The Private Practice by calling (810) 206-1402.